NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals
MWN-AI** Summary
NorthStrive Biosciences, Inc., a subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), recently announced the filing of ten U.S. patent applications aimed at enhancing muscle growth and yield in farmed animals through its proprietary technologies, EL-22 and EL-32. These patents expand the applications of these innovations across various agricultural sectors including livestock, aquaculture, and poultry.
The patent filings include five applications for each of the EL-22 and EL-32 technologies. Two of the applications pertain specifically to their use as non-feed additive supplements to promote muscle tissue growth and enhance weight yield per animal. This could potentially transform livestock practices by yielding higher returns on individual animal weight.
Additionally, applications have been made focusing on reducing gaseous emissions from livestock. This not only addresses environmental concerns but also aims to mitigate health risks like ruminal tympany, which can affect livestock productivity.
In aquaculture, the patents explore the use of EL-22 and EL-32 to stimulate muscle growth in aquatic species, accelerating the time to reach commercially viable sizes while minimizing energy expenditures. Complementarily, other applications target emissions reduction in aquaculture settings to help combat eutrophic conditions.
Lastly, the patent applications cover poultry management, focusing on improving muscle yield per bird using these innovative technologies while ensuring standard growth timelines are maintained.
NorthStrive’s lead technology, EL-22, utilizes an engineered probiotic approach, originally aimed at preserving muscle during weight loss treatments. The company's efforts signal a potential shift in animal agriculture toward more efficient practices. As these applications move through the patent process, NorthStrive aims to establish a competitive edge in the evolving animal health and agricultural markets.
MWN-AI** Analysis
NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., has recently filed ten U.S. patent applications related to their innovative muscle growth technologies, EL-22 and EL-32. This strategic move positions the company to capitalize on the burgeoning animal health and agricultural sectors, which present significant market growth opportunities. As the global demand for efficient livestock production rises, NorthStrive's technologies aim to enhance muscle yield and animal health—critical features that could attract attention from livestock producers and aquaculturists.
The company's focus on both muscle growth and emissions reduction aligns with broader environmental sustainability goals in agriculture. By addressing livestock emissions and potential health risks like ruminal tympany, NorthStrive enhances its appeal as a solution provider in an industry increasingly scrutinized for its environmental impact. Investors should note that these patents cover a vast range of farmed animals, including livestock, poultry, and aquatic species, which diversifies their market reach and decreases reliance on a single segment.
However, while the potential for growth is substantial, investors must also exercise caution. The path from patent applications to marketable products can be fraught with regulatory hurdles and competition. Given the forward-looking nature of the accompanying statements, potential investors should remain vigilant about the risks and uncertainties that accompany biotech ventures, particularly those related to operational performance and regulatory landscapes.
In conclusion, NorthStrive represents a promising opportunity in the agricultural biotech arena, with its dual focus on productivity and sustainability. Those considering an investment should weigh the potential for significant returns against the inherent risks of biotechnology development. Monitoring upcoming developments, regulatory decisions, and the competitive landscape will be crucial in evaluating the company’s growth trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEWPORT BEACH, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences, Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced the filing of ten (10) new U.S. patent applications expanding its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, including applications designed to encourage animals to grow new muscle and increase muscle weight return per animal.
These ten (10) patent applications include five (5) new patent applications covering EL-22 and five (5) new, corresponding applications covering EL-32 across multiple farmed animal categories, including livestock, aquaculture, and poultry.
Muscle Growth and Increased Yield in Livestock
Two of the patent applications cover the use of EL-22 and EL-32 as non-feed additive supplements designed to encourage animals to grow new muscle tissue and increase muscle weight return per animal.
- EL-22 – U.S. Application No. 19/541,209
- EL-32 – U.S. Application No. 19/540,888
Livestock Emissions Reduction and Animal Health
Additional applications cover the use of EL-22 and EL-32 to reduce gaseous emissions in livestock, potentially decreasing environmental impact and mitigating ruminal tympany risk.
- EL-22 – U.S. Application No. 19/540,893
- EL-32 – U.S. Application No. 19/540,895
Aquaculture Muscle Growth and Efficiency
Applications have also been filed covering the use of EL-22 and EL-32 in aquaculture to encourage muscle growth in aquatic species, potentially reducing time to commercially viable size and lowering energy expenditures.
- EL-22 – U.S. Application No. 19/540,898
- EL-32 – U.S. Application No. 19/540,900
Aquaculture Emissions Reduction
Additional aquaculture filings address emissions reduction to mitigate eutrophic conditions.
- EL-22 – U.S. Application No. 19/540,905
- EL-32 – U.S. Application No. 19/540,908
Poultry Muscle Development
The final set of applications covers the use of EL-22 and EL-32 in poultry to encourage muscle growth and improve muscle yield per bird within standard growth timelines.
- EL-22 – U.S. Application No. 19/540,913
- EL-32 – U.S. Application No. 19/540,918
About NorthStrive Biosciences Inc.
NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive’s lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
FAQ**
How does NorthStrive Biosciences, Inc. plan to leverage its patent applications for EL-22 and EL-32 in the agricultural markets, particularly in relation to Elevai Labs Inc. (ELAB) strategic goals?
What competitive advantages does NorthStrive believe its EL-and EL-32 technologies bring to the livestock and aquaculture industries, considering Elevai Labs Inc. (ELAB) existing market position?
In what ways will the filing of new patents for EL-22 and EL-enhance NorthStrive's alignment with Elevai Labs Inc. (ELAB) sustainability initiatives in reducing livestock emissions?
How are NorthStrive Biosciences, Inc.'s new patent applications connected to Elevai Labs Inc. (ELAB) broader vision for innovation in animal health and agricultural efficiency?
**MWN-AI FAQ is based on asking OpenAI questions about Elevai Labs Inc. (NASDAQ: ELAB).
NASDAQ: ELAB
ELAB Trading
1.72% G/L:
$0.7446 Last:
118,551 Volume:
$0.7301 Open:
